OA07.02 ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.270
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Continued EGFR -TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients With Locally Progressive Non–small Cell Lung Cancer After Front-Line EGFR -TKI Treatment

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-mutated Non-Small-Cell Lung Cancer With Brain Metastases: A Retrospective Cohort Study

Cancer Management and Research
Oncology
2019English

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy